Literature DB >> 22990961

Cytokines and visceral leishmaniasis: a comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis.

Alinne Silva Andrade Costa1, Graciomar Conceição Costa, Dorlene Maria Cardoso de Aquino, Vitor Rosa Ramos de Mendonça, Aldina Barral, Manoel Barral-Netto, Arlene de Jesus Mendes Caldas.   

Abstract

It is not well established whether cytokine production differs in response to different clinical forms of visceral leishmaniasis (VL). In this work, we performed a cross-sectional study to investigate the plasma levels of cytokines [interferon (IFN)-γ, tumour necrosis factor (TNF)-α, interleukin (IL)-2, IL-4, IL-10 and IL-12] involved in the pathogenesis of VL in 80 subjects from VL endemic areas, including subjects with active VL, subjects with asymptomatic infection, subjects with cured VL and uninfected controls. The patients were recruited by sampling from a referral hospital and by random selection from a population-based cohort study. The results showed significant differences in the plasma concentration of all cytokines between the groups (p < 0.05). Patients with the active disease had higher plasma levels of IL-10, IL-4, INF-γ and TNF-α relative to the other groups and they produced more IL-12 than asymptomatic and cured subjects. Only the IL-2 concentration was higher in the asymptomatic and cured subjects relative to the patients with active disease (p < 0.05). Our results suggest that these cytokines can be used as markers in epidemiological studies conducted in endemic areas to distinguish between different clinical forms of VL. However, their usefulness should be confirmed in investigations conducted in other endemic areas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22990961     DOI: 10.1590/s0074-02762012000600005

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  21 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

Authors:  M S Duthie; J Guderian; A Vallur; A Bhatia; P Lima dos Santos; E Vieira de Melo; A Ribeiro de Jesus; M Todt; D Mondal; R Almeida; S G Reed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-31       Impact factor: 3.267

3.  Leucocytes and Th-associated Cytokine Profile of HIV-Leishmaniasis Co-Infected Persons Attending Abuja Teaching Hospital, Nigeria.

Authors:  Idris Nasir Abdullahi; Anthony Uchenna Emeribe; Hafeez Aderinsayo Adekola; Habiba Yahaya Muhammad; Abdurrahman El-Fulaty Ahmad; Abubakar Umar Anka; Yusuf Mohammed; Shamsuddeen Haruna; Bamidele Soji Oderinde; Halima Ali Shuwa; Adamu Babayo
Journal:  Eurasian J Med       Date:  2020-10

4.  Comparison of serum cytokine levels in symptomatic and asymptomatic HIV-Leishmania coinfected individuals from a Brazilian visceral leishmaniasis endemic area.

Authors:  Diego Lins Guedes; Elis Dionísio da Silva; Maria Carolina Accioly Brelaz Castro; Walter Lins Barbosa Júnior; Ana Victoria Ibarra-Meneses; Achilleas Tsoumanis; Wim Adriaensen; Johan van Griensven; Valéria Rêgo Alves Pereira; Zulma Maria de Medeiros
Journal:  PLoS Negl Trop Dis       Date:  2022-06-17

Review 5.  Immunoregulation in human American leishmaniasis: balancing pathology and protection.

Authors:  K J Gollob; A G Viana; W O Dutra
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

6.  The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14.

Authors:  Priscila L Dos Santos; Fabrícia A de Oliveira; Micheli Luize B Santos; Luana Celina S Cunha; Michelle T B Lino; Michelle F S de Oliveira; Manuela O M Bomfim; Angela Maria Silva; Tatiana R de Moura; Amélia R de Jesus; Malcolm S Duthie; Steven G Reed; Roque P de Almeida
Journal:  PLoS Negl Trop Dis       Date:  2016-01-27

7.  The involvement of TLR2 and TLR4 in cytokine and nitric oxide production in visceral leishmaniasis patients before and after treatment with anti-leishmanial drugs.

Authors:  Mariana Gatto; Mariana Miziara de Abreu; Karen Ingrid Tasca; Marjorie de Assis Golim; Laura Denise Mendes da Silva; José Cláudio Simão; Carlos Magno Castelo Branco Fortaleza; Ângela Maria Victoriano de Campos Soares; Sueli Aparecida Calvi
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

8.  Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance.

Authors:  Théo Araújo-Santos; Bruno B Andrade; Leonardo Gil-Santana; Nívea F Luz; Priscila L Dos Santos; Fabrícia A de Oliveira; Meirielly Lima Almeida; Roseane Nunes de Santana Campos; Patrícia T Bozza; Roque P Almeida; Valeria M Borges
Journal:  Sci Rep       Date:  2017-06-28       Impact factor: 4.379

9.  Interleukin-4 receptor alpha T1432C and A1652G polymorphisms are associated with risk of visceral leishmaniasis.

Authors:  Alireza Ahmadi; Mehrdad Hajilooi; Ghasem Solgi; Mohammad Abasi; Ahad Bazmani; Mohammad Matini; Khosro Sardarian
Journal:  Adv Biomed Res       Date:  2015-09-28

Review 10.  The Contribution of Immune Evasive Mechanisms to Parasite Persistence in Visceral Leishmaniasis.

Authors:  Elisangela Oliveira de Freitas; Fabiana Maria de Souza Leoratti; Célio Geraldo Freire-de-Lima; Alexandre Morrot; Daniel Ferreira Feijó
Journal:  Front Immunol       Date:  2016-04-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.